<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39370126</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2093-2340</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infection &amp; chemotherapy</Title><ISOAbbreviation>Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>Call for Balancing the Risks and Benefits of Immunotherapeutic Agents for Lymphoma during the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>406</StartPage><EndPage>408</EndPage><MedlinePgn>406-408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3947/ic.2024.0105</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chan Mi</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0001-7907-0412</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Wan Beom</ForeName><Initials>WB</Initials><Identifier Source="ORCID">0000-0003-0022-9625</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. wbpark1@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Infect Chemother</MedlineTA><NlmUniqueID>101531537</NlmUniqueID><ISSNLinking>1598-8112</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Infect Chemother. 56:378.</RefSource><PMID Version="1">39370123</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>WBP is associate editor of Infect Chemother; however, he did not involve in the peer reviewer selection, evaluation, and decision process of this article. Otherwise, no potential conflicts of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370126</ArticleId><ArticleId IdType="pmc">PMC11458502</ArticleId><ArticleId IdType="doi">10.3947/ic.2024.0105</ArticleId><ArticleId IdType="pii">56.406</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med. 2020;17:e1003321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7482833</ArticleId><ArticleId IdType="pubmed">32911500</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarfò L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746126</ArticleId><ArticleId IdType="pubmed">33113551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Fittall MW, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJX, Lee RJ, Lee SM, Mckenzie H, Middleton CP, Murugaesu N, Newsom-Davis T, Olsson-Brown AC, Palles C, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Topping O, Turnbull CD, Várnai C, Briggs ADM, Middleton G, Kerr R UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309–1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7444972</ArticleId><ArticleId IdType="pubmed">32853557</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Mott SL, Sutamtewagul G, McCarthy A, Slager SL, Cerhan JR, Ballas Z, Link BK. Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem. 2020;1:537–544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9176078</ArticleId><ArticleId IdType="pubmed">35845010</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksoy S, Dizdar O, Hayran M, Harputluoğlu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma. 2009;50:357–365.</Citation><ArticleIdList><ArticleId IdType="pubmed">19263297</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, Darrall A, DeMarco J, Kostrewa J, Mohr A, Rivas L, Neiders M, Suresh L, Segal BH, Griffiths EA, Ramsperger V, Shen L, Hernandez-Ilizaliturri FJ. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. Blood. 2021;138:811–814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245303</ArticleId><ArticleId IdType="pubmed">34189565</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M, Vitkon R, Keren-Khadmy N, Levin M, Herishanu Y, Avivi I. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5:3053–3061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362658</ArticleId><ArticleId IdType="pubmed">34387648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong H, Choi SM, Jeon YW, Kim TY, Kim S, An TJ, Lim JU, Park CK. The outcome of SARS-CoV-2 infection in patients with lymphoma and the risk factors for the development of pneumonia. Infect Chemother. 2024;56:378–385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11458498</ArticleId><ArticleId IdType="pubmed">39370123</ArticleId></ArticleIdList></Reference><Reference><Citation>Nham E, Hyun H, Seong H, Yoon JG, Noh JY, Song JY, Kim WJ, Cheong HJ. Vaccination Rates of Hospitalized Patients at High Risk of Severe COVID-19: a single-center cross-sectional study. Infect Chemother. 2022;54:787–791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9840960</ArticleId><ArticleId IdType="pubmed">36596686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CM, Choe PG, Kang CK, Jo HJ, Kim NJ, Yoon SS, Kim TM, Park WB, Oh MD. Impact of T-cell engagers on COVID-19-related mortality in B-cell lymphoma patients receiving B-cell depleting therapy. Cancer Res Treat. 2024;56:324–333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10789957</ArticleId><ArticleId IdType="pubmed">37448122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>